Compare RQI & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RQI | STOK |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | N/A | 2019 |
| Metric | RQI | STOK |
|---|---|---|
| Price | $12.24 | $29.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $34.50 |
| AVG Volume (30 Days) | 432.6K | ★ 712.6K |
| Earning Date | 01-01-0001 | 03-17-2026 |
| Dividend Yield | ★ 8.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.68 |
| Revenue | N/A | ★ $205,632,000.00 |
| Revenue This Year | N/A | $430.24 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $43.03 |
| Revenue Growth | N/A | ★ 1128.17 |
| 52 Week Low | $9.17 | $5.35 |
| 52 Week High | $12.64 | $38.69 |
| Indicator | RQI | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 63.47 | 43.22 |
| Support Level | $12.01 | $28.75 |
| Resistance Level | $12.25 | $30.96 |
| Average True Range (ATR) | 0.17 | 2.05 |
| MACD | 0.04 | -0.34 |
| Stochastic Oscillator | 93.04 | 33.14 |
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.